The global pulmonary drug delivery devices/systems market is expected to reach USD 55.1 billion by 2025, according to a new report by Grand View Research, Inc., Increasing prevalence of chronic respiratory diseases is expected to boost the adoption of Pulmonary Drug Delivery Systems (PDDS). As per WHO, 235 million people suffer from asthma globally. Majority of the asthma related deaths occur in middle- to low-income countries due to lack of treatment options. This shows the potential demand for pulmonary drug delivery systems in the coming years.
Technological advancements in the field of drug delivery are expected to positively impact the pulmonary drug delivery devices market. These advancements include incorporation of agglomerated vesicle technology, MDI electronic dose counter, particle engineering, and supercritical fluid technology. Rising demand for new products, changing lifestyle, ease of use, and better facilities are factors expected to provide lucrative opportunities.
Furthermore, rise in number of public and private organizations is another major factor propelling the growth of pulmonary drug delivery devices market. For instance, organizations such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) are engaged in providing information in clinical and basic research on allergy, asthma, and clinical immunology. Such initiatives are in turn expected to increase the market demand for respiratory drug delivery devices in developing regions, thereby boosting overall market growth.
To request a sample copy or view summary of this report, click the link below:
Further Key Findings From the Study Suggest:
Metered dose inhaler segment held the dominant share owing to its low cost and high adoption rate due to early introduction in the market
Chronic Obstructive Pulmonary Diseases (COPD) segment is anticipated to grow at a lucrative CAGR due to the presence of favorable reimbursement policies for treatment of COPD
High number of patients affected by asthma in developing and developed regions is likely to support the development of asthma applications for respiratory drug delivery devices
E-commerce segment is expected to witness lucrative growth. Development of this segment is supported by its associated benefits such as convenience, discounts, and flexibility
Home care segment is expected to exhibit exponential growth due to the introduction of technologically advanced, portable, and small-sized devices that can be used at home
Asia Pacific region is anticipated to grow at a lucrative CAGR. High prevalence of COPD, indicating a substantial socioeconomic burden in this region drives the growth in Asia Pacific
The market is progressing due to the rising demand for better treatment options, efficient drug delivery, and rapid treatment of local respiratory disorders
Grand View Research has segmented the pulmonary drug delivery systems market on the basis of product, application, distribution channel, end use, and region:
Pulmonary Drug Delivery Systems Product Outlook (Revenue, USD Million, 2014 - 2025)
Metered Dose Inhalers (MDIs)
Dry Powder Inhalers (DPIs)
Pulmonary Drug Delivery Systems Application Outlook (Revenue, USD Million, 2014 - 2025)
Pulmonary Drug Delivery Systems Distribution Channel Outlook (Revenue, USD Million, 2014 - 2025)
Pulmonary Drug Delivery Systems End Use Outlook (Revenue, USD Million, 2014 - 2025)
Hospitals & Clinic
Pulmonary Drug Delivery Systems Regional Outlook (Revenue, USD Million, 2014 - 2025)
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."